In line with this microenvironment-centric strategy, CAR-Ts engineered to co-express CXCR4 demonstrate superior antitumor activity, with improved stromal trafficking and concomitant reductions in MDSC ingress, yielding more durable tumor control than conventional CAR T cells 59. Here, CXCR4 is linked to neoplasm.